for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ジョンソン・エンド・ジョンソン

JNJ.N

現在値

150.13USD

変化

0.04(+0.03%)

出来高

2,181,566

本日のレンジ

149.15

 - 

150.48

52週レンジ

126.10

 - 

154.25

∙ 約20分前の相場を表示しています。

適時開示

J&J Says On Feb 11, Board Voted To Submit Proposal At Annual Meeting Recommending Approval Of Amendment To Co's Restated Certificate Of Incorporation

Feb 13 (Reuters) - Johnson & Johnson <JNJ.N>::J&J - ON FEB 11, BOARD VOTED TO SUBMIT PROPOSAL AT ANNUAL MEETING RECOMMENDING APPROVAL OF AMENDMENT TO CO'S RESTATED CERTIFICATE OF INCORPORATION.J&J - PROPOSAL RECOMMENDS APPROVAL TO DELETE PROVISION PROVIDING THAT NO DIRECTOR MAY BE REMOVED BY VOTE OF SHAREHOLDERS, EXCEPT FOR CAUSE.J&J - PROPOSED AMENDMENT WILL BE SET FORTH IN DETAIL IN CO'S 2020 PROXY STATEMENT, WHICH WILL BE FILED IN ADVANCE OF 2020 ANNUAL MEETING.J&J - IN EVENT PROPOSED AMENDMENT IS APPROVED & BECOMES EFFECTIVE, BOARD WILL APPROVE A CONFORMING AMENDMENT TO CO'S BY-LAWS.

Johnson & Johnson partners with U.S. Department Of Health & Human Services to develop coronavirus vaccine

Feb 11 (Reuters) - Johnson & Johnson <JNJ.N>::JOHNSON & JOHNSON ANNOUNCES COLLABORATION WITH U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES TO ACCELERATE DEVELOPMENT OF A POTENTIAL NOVEL CORONAVIRUS VACCINE.J&J - "WORKING CLOSELY WITH GLOBAL PARTNERS TO SCREEN ITS LIBRARY OF ANTIVIRAL MOLECULES TO ACCELERATE DISCOVERY OF POTENTIAL COVID-19 TREATMENTS".J&J - JANSSEN AND BARDA WILL BOTH CONTRIBUTE TO RESEARCH AND DEVELOPMENT COSTS TO ADVANCE INITIAL STAGES OF COVID-19 VACCINE DEVELOPMENT PROGRAM.J&J - BARDA WILL PROVIDE FUNDING TO SUPPORT ACCELERATED DEVELOPMENT OF A VACCINE CANDIDATE INTO PHASE 1 CLINICAL STUDIES.J&J - AGREEMENT ALSO HAS OPTIONS FOR ADDITIONAL FUNDING FROM BARDA TO PROGRESS A PROMISING CANDIDATE.

Janssen Announces Submission To U.S. FDA For New Darzalex-Based Combination Regimen

Feb 10 (Reuters) - Johnson & Johnson <JNJ.N>::JANSSEN ANNOUNCES SUBMISSION TO U.S. FDA FOR NEW DARZALEX® (DARATUMUMAB)-BASED COMBINATION REGIMEN FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA.JANSSEN ONCOLOGY - SUBMISSION OF SUPPLEMENTAL BLA TO FDA SEEKING APPROVAL OF DARZALEX IN COMBINATION WITH KYPROLIS & DEXAMETHASONE.

Janssen Announces European Commission Approval For Expanded Use Of Erleada

Jan 29 (Reuters) - Janssen: :JANSSEN ANNOUNCES EUROPEAN COMMISSION APPROVAL FOR EXPANDED USE OF ERLEADA FOR TREATMENT OF PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER.EC APPROVAL BASED ON DATA FROM PHASE 3 TITAN STUDY, WHICH ASSESSED ADDITION OF APALUTAMIDE TO ADT IN A BROAD RANGE OF PATIENTS WITH MHSPC.APALUTAMIDE PLUS ADT SIGNIFICANTLY IMPROVED OS COMPARED TO PLACEBO PLUS ADT WITH A 33 PERCENT REDUCTION IN THE RISK OF DEATH.

Health Canada Approved Stelara For Treatment Of Adult Patients With Moderately To Severely Active Ulcerative Colitis

Jan 27 (Reuters) - Janssen Pharmaceutical::JANSSEN - HEALTH CANADA HAS APPROVED STELARA FOR TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS.

Janssen Says European Commission Approves Expanded Use Of Stelara For Treatment Of Paediatric Patients With Moderate To Severe Plaque Psoriasis

Jan 23 (Reuters) - JANSSEN::JANSSEN - EUROPEAN COMMISSION APPROVES EXPANDED USE OF STELARA FOR TREATMENT OF PAEDIATRIC PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS.

J&J Says Will Not Be Active Participant At FDA Hearing On Talc Testing Methods In Feb

Jan 22 (Reuters) - Johnson & Johnson <JNJ.N>::EXEC SAYS OVER 3,500 PATIENTS HAVE BEEN TREATED TO DATE WITH SPRAVATO AND PATIENT DEMAND CONTINUES TO BUILD - CONF CALL.CEO SAYS CO IS OPTIMIZING RESOURCES TO SAVE WATER AND ELECTRICITY AND EXPECTS TO REDUCE CARBON EMISSIONS BY 20% IN 2020 - CONF CALL.EXEC SAYS EXPECTS FREE CASH FLOW TO DECLINE IN 2020 DUE TO PAYMENT OF PREVIOUSLY DISCLOSED OPIOID LITIGATION - CONF CALL.EXEC SAYS 2020 FORECAST DOES NOT ASSUME ANY MAJOR ACQUISITIONS OR OTHER MAJOR USES OF CASH - CONF CALL.SAYS OFF-PATENT DRUGS WERE ABLE TO RETAIN BUSINESS A LITTLE LONGER THAN EXPECTED IN 2019, AND EXPECTS IT TO CONTINUE IN 2020 - CONF CALL.SAYS REMAINS "CAUTIOUSLY OPTIMISTIC" REGARDING OPIOID SETTLEMNT AND EXPECTS TO HEAR MORE UPDATES IN COMING MONTHS - CONF CALL.SAYS INDEPENDENT RESEARCH CONTINUES TO FIND NO LINK BETWEEN TALC AND CANCER - CONF CALL.SAYS CONTINUES TO WORK WITH NEGOTIATING COMMITTEE OF STATE ATTORNEYS GENERAL TO FINALIZE OPIOID SETTLEMENT AGREEMENT- CONF CALL.SAYS CO WILL NOT BE ACTIVE PARTICIPANT AT FDA EXPERT PANEL MEETING NEXT MONTH FOR DISCUSSING TESTING METHODS FOR DETECTING ASBESTOS IN TALC - CONF CALL.SAYS CO'S CURRENT INTERNAL TESTING METHODS FOR DETECTING ASBESTOS EXCEED THAT OF CURRENT FDA STANDARDS FOR COSMETIC TALC - CONF CALL.

Johnson & Johnson Reports Q4 Adjusted Earnings Per Share $1.88

Jan 22 (Reuters) - Johnson & Johnson <JNJ.N>::REPORTS 2019 FOURTH-QUARTER AND FULL YEAR RESULTS:.Q4 SALES $20.7 BILLION VERSUS REFINITIV IBES ESTIMATE OF $20.8 BILLION.Q4 ADJUSTED EARNINGS PER SHARE $1.88.Q4 EARNINGS PER SHARE $1.50.Q4 EARNINGS PER SHARE ESTIMATE $1.87 -- REFINITIV IBES DATA.J&J - COMPANY PROJECTS CONTINUED SALES AND EARNINGS GROWTH IN 2020 GUIDANCE.J&J - QTRLY WORLDWIDE REMICADE SALES $1.04 BILLION VERSUS $1.24 BILLION REPORTED LAST YEAR.J&J SEES 2020 OPERATIONAL SALES $85.8 TO $86.6 BILLION.J&J QTRLY WORLDWIDE IMBRUVICA SALES $875 MILLION VERSUS $703 MILLION.J&J SEES 2020 ESTIMATED REPORTED SALES $85.4 TO $86.2 BILLION.J&J SEES 2020 ADJUSTED OPERATIONAL SALES UP 5.0% - 6.0%.J&J QTRLY GAAP LITIGATION EXPENSE, NET $264 MILLION VERSUS $1.29 BILLION.J&J QTRLY WORLDWIDE ZYTIGA SALES $677 MILLION VERSUS $786 MILLION.FY2020 REVENUE VIEW $85.48 BILLION -- REFINITIV IBES DATA.J&J QTRLY WORLDWIDE DARZALEX SALES $830 MILLION VERSUS $584 MILLION.J&J SEES FY2020 ADJUSTED OPERATIONAL EPS (DILUTED) $9.00 TO $9.15.J&J SEES FY2020 ADJUSTED EPS (DILUTED) $8.95 TO $9.10.FY2020 EARNINGS PER SHARE VIEW $9.10 -- REFINITIV IBES DATA.

U.S. Court Knocks Down Risperdal Verdict Against J&J's Janssen Unit To $6.8 Million From $8 Billion - Law.Com

Jan 17 (Reuters) - :U.S. COURT KNOCKS DOWN RISPERDAL VERDICT AGAINST JOHNSON & JOHNSON'S JANSSEN UNIT TO $6.8 MILLION FROM $8 BILLION - LAW.COM.

Janssen Seeks Expanded Use Of Spravato (Esketamine) Nasal Spray In Europe

Jan 15 (Reuters) - Janssen Pharmaceutical Companies of Johnson & Johnson::JANSSEN SEEKS EXPANDED USE OF SPRAVATO®▼ (ESKETAMINE) NASAL SPRAY IN EUROPE AS A TREATMENT FOR DEPRESSIVE SYMPTOMS IN ADULTS WITH MAJOR DEPRESSIVE DISORDER WHO HAVE CURRENT SUICIDAL IDEATION WITH INTENT.JANSSEN - SUBMISSION OF TYPE II VARIATION APPLICATION IS BASED ON RESULTS FROM 2 PHASE 3 CLINICAL STUDIES.JANSSEN - ANNOUNCED SUBMISSION OF A TYPE II VARIATION APPLICATION TO EUROPEAN MEDICINES AGENCY FOR SPRAVATO (ESKETAMINE) NASAL SPRAY.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up